MX2016000646A - Sulfonamidas como moduladores de canales de sodio. - Google Patents

Sulfonamidas como moduladores de canales de sodio.

Info

Publication number
MX2016000646A
MX2016000646A MX2016000646A MX2016000646A MX2016000646A MX 2016000646 A MX2016000646 A MX 2016000646A MX 2016000646 A MX2016000646 A MX 2016000646A MX 2016000646 A MX2016000646 A MX 2016000646A MX 2016000646 A MX2016000646 A MX 2016000646A
Authority
MX
Mexico
Prior art keywords
sodium channels
sulfonamides
modulators
compounds
pharmaceutically acceptable
Prior art date
Application number
MX2016000646A
Other languages
English (en)
Other versions
MX364155B (es
Inventor
Sara Sabina Hadida-Ruah
Brian Richard Bear
Vijayalaksmi Arumugam
Corey Anderson
Andreas P Termin
James Philip Johnson
Paul Krenitsky
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2016000646A publication Critical patent/MX2016000646A/es
Publication of MX364155B publication Critical patent/MX364155B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)

Abstract

La invención se refiere a compuestas de fórmula I o a sales farmacéuticamente aceptables de los mismos, útiles como inhibidores de canales de sodio: (ver Fórmula) La invención también proporciona composiciones farmacéuticamente aceptables que comprenden los compuestos de la invención y métodos de uso de las composiciones en el tratamiento de diversos trastornos, incluyendo dolor.
MX2016000646A 2013-07-19 2014-07-18 Sulfonamidas como moduladores de canales de sodio. MX364155B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856146P 2013-07-19 2013-07-19
PCT/US2014/047265 WO2015010065A1 (en) 2013-07-19 2014-07-18 Sulfonamides as modulators of sodium channels

Publications (2)

Publication Number Publication Date
MX2016000646A true MX2016000646A (es) 2016-05-26
MX364155B MX364155B (es) 2019-04-12

Family

ID=51293175

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000646A MX364155B (es) 2013-07-19 2014-07-18 Sulfonamidas como moduladores de canales de sodio.

Country Status (24)

Country Link
US (1) US11203571B2 (es)
EP (1) EP3022175B1 (es)
JP (1) JP6337109B2 (es)
KR (1) KR102215620B1 (es)
CN (1) CN105683157B (es)
AP (1) AP2016009023A0 (es)
AU (1) AU2014290411B2 (es)
BR (1) BR112016000825B1 (es)
CA (1) CA2918365C (es)
CL (1) CL2016000106A1 (es)
EC (1) ECSP16005566A (es)
ES (1) ES2654393T3 (es)
GE (1) GEP20207102B (es)
HU (1) HUE037876T2 (es)
IL (1) IL243671B (es)
MX (1) MX364155B (es)
NO (1) NO2918662T3 (es)
PE (1) PE20160548A1 (es)
PH (1) PH12016500105A1 (es)
RU (1) RU2680401C2 (es)
SG (1) SG11201600383SA (es)
UA (1) UA119147C2 (es)
WO (1) WO2015010065A1 (es)
ZA (1) ZA201600380B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710111A (en) 2013-01-31 2020-08-28 Vertex Pharma Quinoline and quinoxaline amides as modulators of sodium channels
SMT201700256T1 (it) 2013-01-31 2017-09-07 Vertex Pharma Piridone ammidi come modulatori di canali del sodio
JP6337109B2 (ja) 2013-07-19 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤としてのスルホンアミド
JP6463580B2 (ja) 2013-12-13 2019-02-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
AU2015242219A1 (en) 2014-03-29 2016-10-06 Lupin Limited Sulfonamide compounds as Voltage gated sodium channel modulators
BR112019024016A2 (pt) * 2017-05-16 2020-06-09 Vertex Pharma amidas de piridona deuteradas e profármacos das mesmas como moduladores de canais de sódio
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
EP3752152A1 (en) 2018-02-12 2020-12-23 Vertex Pharmaceuticals Incorporated A method of treating pain
CA3105748A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
CA3105657A1 (en) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
US12344595B2 (en) 2018-11-02 2025-07-01 Merck Sharp & Dohme Llc 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
EP3873893A1 (en) 2018-11-02 2021-09-08 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
DK4069691T3 (da) 2019-12-06 2024-10-28 Vertex Pharma Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
JP2023530319A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド
IL299180A (en) 2020-06-17 2023-02-01 Merck Sharp & Dohme Llc 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS
BR112023018313A2 (pt) * 2021-03-11 2023-12-12 Latigo Biotherapeutics Inc Compostos de piridina e piridazina metil-substituída, derivados destes e métodos de seu uso
CA3217565A1 (en) 2021-05-07 2022-11-10 Ashok Arasappan Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
JP2024520649A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
MA64853B1 (fr) 2021-06-04 2025-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
EP4347033A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
AU2023255771A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
EP4511115A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023207949A1 (zh) * 2022-04-25 2023-11-02 中国科学院上海药物研究所 并环类化合物及其应用
CR20240512A (es) 2022-04-25 2025-03-03 Siteone Therapeutics Inc Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor
TW202406894A (zh) 2022-08-12 2024-02-16 大陸商廣州費米子科技有限責任公司 用作電壓門控鈉通道抑制劑的化合物
EP4630405A1 (en) 2022-12-06 2025-10-15 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
AU2024257755A1 (en) * 2023-04-19 2025-11-13 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nav1.8 inhibitors, preparation method therefor and use thereof
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
EP1303757B1 (en) 2000-07-10 2006-10-11 Vertex Pharmaceuticals (San Diego) LLC Ion channel assay methods
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
KR20060073930A (ko) 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
BRPI0513717A (pt) 2004-07-23 2008-05-13 Pfizer derivados de piridina
TWI285415B (en) * 2005-08-01 2007-08-11 Advanced Semiconductor Eng Package structure having recession portion on the surface thereof and method of making the same
KR20080109918A (ko) * 2006-04-11 2008-12-17 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
EP2227453B1 (en) 2007-10-11 2016-03-09 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
RU2010118467A (ru) 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов
RU2010118481A (ru) 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2012007836A1 (en) * 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
TWI520964B (zh) 2011-02-02 2016-02-11 維泰克斯製藥公司 作為離子通道調節劑之吡咯并吡－螺環哌啶醯胺
AU2012217616B2 (en) 2011-02-18 2017-03-02 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
AU2012273133A1 (en) * 2011-06-20 2013-11-07 E. I. Du Pont De Nemours And Company Heterocyclic compounds for treating helminth infections
US9365588B2 (en) 2011-11-04 2016-06-14 Vertex Pharmaceuticals Incorporated Benzoxazines as modulators of ion channels
US9403839B2 (en) 2012-01-16 2016-08-02 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
SMT201700256T1 (it) 2013-01-31 2017-09-07 Vertex Pharma Piridone ammidi come modulatori di canali del sodio
CA2898653C (en) 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
NZ710111A (en) 2013-01-31 2020-08-28 Vertex Pharma Quinoline and quinoxaline amides as modulators of sodium channels
JP6337109B2 (ja) 2013-07-19 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤としてのスルホンアミド
JP6463580B2 (ja) 2013-12-13 2019-02-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels

Also Published As

Publication number Publication date
SG11201600383SA (en) 2016-02-26
NO2918662T3 (es) 2018-01-06
IL243671B (en) 2020-10-29
UA119147C2 (uk) 2019-05-10
HK1223604A1 (en) 2017-08-04
PH12016500105A1 (en) 2016-04-18
MX364155B (es) 2019-04-12
KR102215620B1 (ko) 2021-02-16
CN105683157A (zh) 2016-06-15
RU2016105511A (ru) 2017-08-24
IL243671A0 (en) 2016-04-21
PE20160548A1 (es) 2016-05-21
JP6337109B2 (ja) 2018-06-06
BR112016000825B1 (pt) 2023-04-25
BR112016000825A8 (pt) 2020-01-07
CA2918365C (en) 2021-09-07
AU2014290411B2 (en) 2018-11-15
ES2654393T3 (es) 2018-02-13
GEAP202014060A (en) 2020-01-27
EP3022175B1 (en) 2017-11-08
BR112016000825A2 (pt) 2017-07-25
ZA201600380B (en) 2018-07-25
RU2016105511A3 (es) 2018-04-25
JP2016525122A (ja) 2016-08-22
AU2014290411A1 (en) 2016-01-28
EP3022175A1 (en) 2016-05-25
KR20160032241A (ko) 2016-03-23
ECSP16005566A (es) 2017-02-24
RU2680401C2 (ru) 2019-02-21
US11203571B2 (en) 2021-12-21
HUE037876T2 (hu) 2018-09-28
CL2016000106A1 (es) 2016-07-29
CA2918365A1 (en) 2015-01-22
US20160152561A1 (en) 2016-06-02
AP2016009023A0 (en) 2016-02-29
WO2015010065A1 (en) 2015-01-22
GEP20207102B (en) 2020-05-11
CN105683157B (zh) 2019-07-19
NZ715751A (en) 2021-09-24

Similar Documents

Publication Publication Date Title
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
NZ750187A (en) Pyridone amides as modulators of sodium channels
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
IN2015DN01156A (es)
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
PH12015502161A1 (en) Therapeutic compounds and compositions
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12016501028A1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
EA201590748A1 (ru) Противовирусные соединения против rsv
IN2014KN02601A (es)
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
MX2016002794A (es) Compuestos antiproliferativos.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
EA201600434A1 (ru) Применение производных бензимидазолпролина
MY173573A (en) Pyridin-4-yl derivatives
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов

Legal Events

Date Code Title Description
FG Grant or registration